1. Home
  2. BIO
  3. BIO News

Latest Bio-Rad Laboratories Inc. (BIO) News on June 2, 2025

Bio-Rad’s Management to Host Investor Meetings During Jefferies Global Healthcare Conference
BIO

Business Wire

4 days ago

Bio-Rad’s Management to Host Investor Meetings During Jefferies Global Healthcare Conference

BIO

Argus Research

13 days ago

BIO: Lowering target price to $259.00

BIO

Argus Research

20 days ago

BIO: Raising target price to $266.00

Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends
BIO

Zacks

20 days ago

Investing in Bio-Rad (BIO)? Don't Miss Assessing Its International Revenue Trends

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference
BIO

Business Wire

21 days ago

Bio-Rad's Management to Participate in Fireside Chat During 2025 RBC Capital Markets Global Healthcare Conference

Bio-Rad Laboratories First Quarter 2025 Earnings: EPS: US$2.29 (vs US$13.46 in 1Q 2024)
BIO

Simply Wall St.

a month ago

Bio-Rad Laboratories First Quarter 2025 Earnings: EPS: US$2.29 (vs US$13.46 in 1Q 2024)

BIO

Argus Research

a month ago

BIO: Rating increased to a HOLD

Analysts Have Been Trimming Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Price Target After Its Latest Report
BIO

Simply Wall St.

a month ago

Analysts Have Been Trimming Their Bio-Rad Laboratories, Inc. (NYSE:BIO) Price Target After Its Latest Report

BIO

Morningstar Research

a month ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

BIO

Morningstar Research

a month ago

Analyst Report: Bio-Rad Laboratories, Inc.

BIO

Thomson Reuters StreetEvents

a month ago

Q1 2025 Bio Rad Laboratories Inc Earnings Call

BIO

MT Newswires

a month ago

UBS Adjusts Price Target on Bio-Rad Laboratories to $310 From $355, Maintains Buy Rating

BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket
BIO

Zacks

a month ago

BIO Beats on Q1 Earnings, Lowers '25 View, Stock Up in Aftermarket

BIO

MT Newswires

a month ago

RBC Cuts Price Target on Bio-Rad Laboratories to $392 From $409, Keeps Outperform Rating

BIO

MT Newswires

a month ago

Bio-Rad Laboratories Q1 Adjusted Earnings Rise, Revenue Falls

Bio-Rad Laboratories Inc (BIO) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...
BIO

GuruFocus.com

a month ago

Bio-Rad Laboratories Inc (BIO) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...

BIO

Associated Press Finance

a month ago

Bio-Rad: Q1 Earnings Snapshot

Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates
BIO

Zacks

a month ago

Bio-Rad Laboratories (BIO) Q1 Earnings Surpass Estimates

Bio-Rad Reports First-Quarter 2025 Financial Results
BIO

Business Wire

a month ago

Bio-Rad Reports First-Quarter 2025 Financial Results

Bio-Rad Laboratories, Inc. (BIO): Among Billionaire Mason Hawkins’ Small-Cap Stocks with Huge Upside Potential
BIO

Insider Monkey

a month ago

Bio-Rad Laboratories, Inc. (BIO): Among Billionaire Mason Hawkins’ Small-Cap Stocks with Huge Upside Potential

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
BIO

Zacks

a month ago

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
BIO

GlobeNewswire

a month ago

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

BIO

Argus Research

a month ago

BIO: What does Argus have to say about BIO?

Does Bio-Rad Laboratories (BIO) Offer a Solid Financial Profile?
BIO

Insider Monkey

a month ago

Does Bio-Rad Laboratories (BIO) Offer a Solid Financial Profile?

Should You be Optimistic on Bio-Rad Laboratories’s (BIO) Outlook?
BIO

Insider Monkey

a month ago

Should You be Optimistic on Bio-Rad Laboratories’s (BIO) Outlook?

BIO

Argus Research

2 months ago

BIO: Raising target price to $196.00

Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
BIO

Business Wire

2 months ago

Bio-Rad to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025

BIO

Morningstar Research

2 months ago

Analyst Report: Bio-Rad Laboratories, Inc.

BIO

Argus Research

2 months ago

BIO: Lowering target price to $176.00

BIO

MT Newswires

2 months ago

RBC Cuts Price Target on Bio-Rad Laboratories to $409 From $430, Keeps Outperform Rating

BIO

Morningstar Research

2 months ago

Analyst Report: Bio-Rad Laboratories, Inc.

Further weakness as Bio-Rad Laboratories (NYSE:BIO) drops 5.0% this week, taking three-year losses to 61%
BIO

Simply Wall St.

2 months ago

Further weakness as Bio-Rad Laboratories (NYSE:BIO) drops 5.0% this week, taking three-year losses to 61%

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
BIO

Zacks

2 months ago

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

BIO

Argus Research

2 months ago

BIO: Lowering target price to $192.00

Bio-Techne Opens New Customer Experience Centre in Germany
BIO

Zacks

2 months ago

Bio-Techne Opens New Customer Experience Centre in Germany

Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
BIO

Zacks

2 months ago

Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate

BIO

Argus Research

2 months ago

BIO: Rating decreased to a SELL

Alger Russell Innovation Index Updates for First Quarter 2025
BIO

PR Newswire

3 months ago

Alger Russell Innovation Index Updates for First Quarter 2025

Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%
BIO

Simply Wall St.

3 months ago

Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%

Is Bio-Rad Laboratories, Inc. (BIO) the Best Medical Technology Stock to Buy According to Analysts?
BIO

Insider Monkey

3 months ago

Is Bio-Rad Laboratories, Inc. (BIO) the Best Medical Technology Stock to Buy According to Analysts?

BIO

Argus Research

3 months ago

BIO: Lowering target price to $263.00

Bio-Rad (BIO) International Revenue Performance Explored
BIO

Zacks

3 months ago

Bio-Rad (BIO) International Revenue Performance Explored

BIO

Argus Research

3 months ago

BIO: Lowering target price to $291.00

HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket
BIO

Zacks

3 months ago

HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
BIO

Zacks

3 months ago

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips
BIO

Zacks

3 months ago

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y
BIO

Zacks

3 months ago

EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises
BIO

Zacks

3 months ago

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

BIO

Argus Research

3 months ago

BIO: Rating increased to a HOLD

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles
BIO

Zacks

3 months ago

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

BIO Stock Might Rise Following the Offer to Acquire Stilla
BIO

Zacks

3 months ago

BIO Stock Might Rise Following the Offer to Acquire Stilla

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
BIO

Zacks

4 months ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Bio-Rad price target lowered to $447 from $477 at RBC Capital
BIO

TipRanks

4 months ago

Bio-Rad price target lowered to $447 from $477 at RBC Capital

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations
BIO

Simply Wall St.

4 months ago

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

BIO

Morningstar Research

4 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket
BIO

Zacks

4 months ago

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Bio-Rad set to acquire Stilla Technologies
BIO

Medical Device Network

4 months ago

Bio-Rad set to acquire Stilla Technologies

BIO

Morningstar Research

4 months ago

Analyst Report: Bio-Rad Laboratories, Inc.

BIO

MT Newswires

4 months ago

UBS Adjusts Price Target on Bio-Rad Laboratories to $355 From $390, Keeps Buy Rating

BIO

MT Newswires

4 months ago

RBC Cuts Price Target on Bio-Rad Laboratories to $447 From $477, Keeps Outperform Rating

BIO

Thomson Reuters StreetEvents

4 months ago

Q4 2024 Bio Rad Laboratories Inc Earnings Call

Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls
BIO

Zacks

4 months ago

Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...
BIO

GuruFocus.com

4 months ago

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates
BIO

Zacks

4 months ago

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

BIO

Associated Press Finance

4 months ago

Bio-Rad: Q4 Earnings Snapshot

BIO

MT Newswires

4 months ago

Bio-Rad Laboratories' Q4 Adjusted Earnings, Revenue Fall

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise
BIO

Zacks

4 months ago

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Report Preview: What To Look For
BIO

GuruFocus.com

4 months ago

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Report Preview: What To Look For

OncoCyte prices $29.1M equity offering
BIO

TipRanks

4 months ago

OncoCyte prices $29.1M equity offering

Oncocyte Prices $29.1 Million Equity Offering
BIO

GlobeNewswire

4 months ago

Oncocyte Prices $29.1 Million Equity Offering

Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises
BIO

Zacks

4 months ago

Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand
BIO

Zacks

4 months ago

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase
BIO

Zacks

4 months ago

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline
BIO

Zacks

4 months ago

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance
BIO

Zacks

4 months ago

Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance

BIO

Argus Research

4 months ago

BIO: Lowering target price to $279.00

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?
BIO

Zacks

4 months ago

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

BIO

MT Newswires

4 months ago

RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating

BIO

Argus Research

4 months ago

BIO: Raising target price to $294.00

Bio-Rad Laboratories, Inc. (BIO): Is This Healthcare Stock A Good Buy?
BIO

Insider Monkey

4 months ago

Bio-Rad Laboratories, Inc. (BIO): Is This Healthcare Stock A Good Buy?

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
BIO

Business Wire

4 months ago

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

BIO

Argus Research

4 months ago

BIO: Lowering target price to $283.00

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
BIO

Zacks

5 months ago

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now
BIO

Zacks

5 months ago

Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now

BIO

Argus Research

5 months ago

BIO: Raising target price to $294.00

BIO

MT Newswires

5 months ago

Bio-Rad Laboratories Led $105 Million Series C Funding Round for Geneoscopy

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests
BIO

Business Wire

5 months ago

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference
BIO

Business Wire

5 months ago

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

At US$331, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?
BIO

Simply Wall St.

5 months ago

At US$331, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

BIO

Argus Research

5 months ago

BIO: Rating increased to a HOLD

BIO

Argus Research

6 months ago

BIO: Lowering target price to $277.00

BIO

Argus Research

6 months ago

BIO: Lowering target price to $278.00

BIO

MT Newswires

6 months ago

RBC Raises Price Target on Bio-Rad Laboratories to $481 From $469, Keeps Outperform Rating

BIO

Argus Research

6 months ago

BIO: Raising target price to $291.00

Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?
BIO

Zacks

6 months ago

Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?

Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)
BIO

Simply Wall St.

6 months ago

Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory
BIO

Insider Monkey

6 months ago

Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference
BIO

Business Wire

6 months ago

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity?
BIO

Insider Monkey

7 months ago

What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity?

BIO

Argus Research

7 months ago

BIO: Lowering target price to $292.00

Share on Social Networks: